Universität zu Köln

Borrega, Jorge Garcia, Boell, Boris, Kochanek, Matthias, Naendrup, Jan-Hendrik, Simon, Florian, Sieg, Noelle, Hallek, Michael, Borchmann, Peter, Holtick, Udo, Shimabukuro-Vornhagen, Alexander, Eichenauer, Dennis A. and Heger, Jan-Michel ORCID: 0000-0001-9463-8504 (2023). Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis. Ann. Hematol., 102 (1). S. 191 - 198. NEW YORK: SPRINGER. ISSN 1432-0584

Full text not available from this repository.

Abstract

High-dose chemotherapy and autologous stem cell transplantation (ASCT) can be associated with adverse events necessitating treatment on the intensive care unit (ICU). Data focusing on patients admitted to the ICU during hospitalization for high-dose chemotherapy and ASCT are scarce. We thus conducted a single-center retrospective analysis comprising 79 individuals who had high-dose chemotherapy and ASCT between 2014 and 2020 and were admitted to the ICU between the initiation of conditioning therapy and day 30 after ASCT. The median age was 57 years (range: 20-82 years); 38% of patients were female. B-cell non-Hodgkin lymphoma (34%) and plasma cell disorders (28%) were the most common indications for high-dose chemotherapy and ASCT. Sepsis represented the major cause for ICU admission (68%). Twenty-nine percent of patients required mechanical ventilation (MV), 5% had renal replacement therapy, and 44% needed vasopressors. The ICU, hospital, 90-day, and 1-year survival rates were 77.2%, 77.2%, 72.2%, and 60.3%, respectively. Stable disease or disease progression prior to the initiation of high-dose chemotherapy (p = 0.0028) and MV (p < 0.0001) were associated with an impaired survival. A total of 36 patients died during observation. The most frequent causes of death were the underlying malignancy (44%) and sepsis (39%). Taken together, the present analysis indicates a favorable overall outcome for patients admitted to the ICU during hospitalization for high-dose chemotherapy and ASCT. Thus, this patient group should not be denied admission and treatment on the ICU.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Borrega, Jorge Garcia UNSPECIFIED UNSPECIFIED UNSPECIFIED Boell, Boris UNSPECIFIED UNSPECIFIED UNSPECIFIED Kochanek, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Naendrup, Jan-Hendrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Simon, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Sieg, Noelle UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Holtick, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED Shimabukuro-Vornhagen, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Heger, Jan-Michel UNSPECIFIED orcid.org/0000-0001-9463-8504 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-660670
DOI:	10.1007/s00277-022-05028-x
Journal or Publication Title:	Ann. Hematol.
Volume:	102
Number:	1
Page Range:	S. 191 - 198
Date:	2023
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0584
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CRITICALLY-ILL PATIENTS; PREDICTORS; MORTALITY; SURVIVAL Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66067